The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2023 | Genomic evolution and resistance to pirtobrutinib in CLL: insights from the BRUIN study
William Wierda, MD, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses an analysis from the BRUIN study (NCT03740529) that investigated the genomic evolution of pirtobrutinib resistance in previously treated patients with chronic lymphocytic leukemia (CLL). The analysis included CLL patients who received pirtobrutinib monotherapy after progression on covalent BTK inhibitors. Genomic sequencing revealed the clearance of BTK C481 clones and the emergence of non-C481 clones, particularly gatekeeper T474 and kinase-impaired L528W mutations. The study suggests that alternative resistance mechanisms may also exist and further investigation is needed to better understand the mechanisms of resistance to pirtobrutinib. This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Contracted Research: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Bristol-Myers Squibb Company, Cyclacel Pharmaceuticals Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, GlaxoSmithKline, Janssen Biotech Inc, Juno Therapeutics, a Celgene Company, Kite, A Gilead Company, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Miragen Therapeutics Inc, Novartis, Oncternal Therapeutics, Pharmacyclics LLC, an AbbVie Company, Sunesis Pharmaceuticals Inc, Xencor; Nonrelevant Financial Relationship: National Comprehensive Cancer Network (Chair, CLL).
